通过来自Janusmed风险概况的决策支持算法识别了潜在的不良药物事件 - - 在瑞典地区的一项以人口为基础的回顾性研究.
Tora Hammar1,2, Emma Jonsén1, Olof Björneld1,2,3
1The eHealth Institute, Department of Medicine and Optometry, Linnaeus University, S-391 82 Kalmar, Sweden.
临床决策支持系统 (CDSS),如Janusmed风险概况,有助于识别患有药物不良事件 (ADE) 风险的患者. 超过20%的患者面临着药物组合的风险,突出了常见的ADE漏洞.
科学领域:
- 药监和药物安全 药监和药物安全
- 医疗信息学 医疗信息学
- 临床药理学 临床药理学
背景情况:
- 药物不良事件 (ADEs) 经常发生,导致显著的发病率和死亡率.
- 有害的药物组合是可预防的ADEs的主要原因.
- 临床决策支持系统 (CDSS) 提供了一种ADE预防策略.
研究的目的:
- 为了确定由Janusmed风险概况CDSS.确定潜在的ADE的流行率.
- 分析9个常见或严重的ADE类别的ADE风险患病率.
- 调查与ADE风险增加相关的人口因素.
主要方法:
- 一个瑞典地区人口的回顾性,横截面研究 (2020年n=246,010).
- 使用了所有分发和使用的药物的数据.
- 采用了Janusmed风险概况CDSS算法和集群分析.
主要成果:
- 超过20%的患者表现出出血,便秘,正统状态或毒性的风险增加.
- 患有增加风险的患者比例在ADE类别中从3.5%到近30%不等.
- 更高的年龄和性别与风险增加有关;集群分析揭示了多个ADE风险的患者群.
结论:
- 在受研究的人群中,具有ADE风险的药物组合普遍存在.
- 年龄和性别影响潜在的ADEs的风险.
- 需要进行进一步的研究,以将确定的风险与实际观察到的ADEs相关联.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Analysis of Population Pharmacokinetic Data
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Factors Affecting Drug Response: Overview
Errors occurring during blood pressure monitoring
Several factors...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
